Allergan plc (NYSE: AGN) revealed that the FDA has accorded its approval to market JUVÉDERM VOLBELLA XC, for use in the lips for lip augmentation and for correction of perioral rhytids, commonly ...

The FINANCIAL — Allergan plc, on June 1 announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLBELLA XC, for use in the lips for lip ...

Perioral Rhytids Allergan announced that the Food and Drug Administration (FDA) has approved Juvederm Volbella XC for use in lip augmentation and for correction of perioral rhytids (referred to as ...

Please provide your email address to receive an email when new articles are posted on . Juvéderm Volbella XC treatment for lip and perioral enhancement was safe and effective, with the effects of ...

(RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced the FDA approval of JUVÉDERM VOLBELLA XC for improvement of infraorbital hollows in adults over the age of 21. JUVÉDERM VOLBELLA XC ...

DALLAS, TX--(Marketwired - October 06, 2016) - Dr. Lori Stetler and Dr. Kristel Polder, of Dallas Center for Dermatology and Aesthetics, are among the first doctors in the United States to perform ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved marketing of Juvéderm Volbella XC for lip augmentation and correcting perioral rhytids in ...

Hyaluronic acid 15mg/mL, 0.3% w/w lidocaine; injectable gel implant. Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to ...

Juvedérm Volbella es el nuevo relleno dérmico de ácido hialurónico con lidocaína –anestésico-, de Allergan. Desarrollado con la tecnología patentada Vycross, está formulado con una innovadora ...